Background: With a recognized increase in the incidence of venous thromboembolism (VTE) in children, especially in those with complex, chronic conditions, it is important for patient safety and risk management to identify subgroups that would benefit from prophylactic treatment. The aim of our study was to assess whether scoliosis surgery in children was associated with an increased incidence of VTE, including deep venous thrombosis (DVT) and pulmonary embolism, and if chemoprophylaxis is warranted.
Methods: We reviewed our institution's Pediatric Orthopaedic Spine Database (1992-2019) to identify patients who had a symptomatic VTE postoperatively.
Results: There were 1471 patients (1035 female, 436 male) with a mean age at surgery of 12.1±3.2 years (range, 1 to 18 y) underwent posterior spinal fusion and instrumentation (2131 procedures). No patients were given pharmacological VTE prophylaxis, and no routine screening for VTE was performed. Two patients had a lower extremity DVT (0.13%) within 6 months following surgery, (range, 55 to 161 d). Neither patient had a subsequent pulmonary embolism. They were 9 and 17 years of age with a diagnosis of neuromuscular scoliosis (1 each postpolio and myelodysplasia). One affected patient had a central venous line inserted perioperatively, a known risk factor for thromboembolism. All DVTs were treated with appropriately dosed anticoagulants. None had a family history of hypercoagulation.
Conclusions: The risk of symptomatic VTE is extraordinarily low after pediatric spinal deformity surgery. Mechanical prophylaxis is sufficient in most cases. Further multi-center studies may help identify patient specific risk factors.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/BPO.0000000000001746 | DOI Listing |
Res Pract Thromb Haemost
January 2025
Section of Hematology & Medical Oncology, Boston University School of Medicine, Boston, Massachusetts, USA.
Background: Cancer-associated thrombosis (CAT) is a leading cause of death in patients diagnosed with cancer. However, pharmacologic thromboprophylaxis use in cancer patients must be carefully evaluated due to a 2-fold increased risk of experiencing a major bleeding event within this population. The electronic health record CAT (EHR-CAT) risk assessment model (RAM) was recently developed, and reports improved performance over the widely used Khorana score.
View Article and Find Full Text PDFJ Intensive Care Med
January 2025
Servicio de Angiología, cirugía vascular y endovascular. Hospital Universitario Vall d'Hebron, Barcelona, Spain.
Background: Venous thromboembolism (VTE), whether pulmonary embolism (PE) or deep vein thrombosis (DVT), is common in patients with COVID-19. Recommendations on systematic screening in the intensive care unit (ICU) are lacking.
Research Question: Is there any clinical benefit of systematic screening for DVT in critically ill patients with severe COVID-19?
Study Design And Methods: Single-center randomized clinical trial (RCT) of COVID-19 cases admitted to the ICU.
J Cardiovasc Pharmacol Ther
January 2025
Department of Internal Medicine, Kilimanjaro Christian Medical University College, Moshi, Tanzania.
Background: Vitamin K antagonists (VKA) continue to be the principal anticoagulants for both the treatment and prevention of venous thromboembolism. The use of VKA often requires regular monitoring to avoid over-anticoagulation and prevent thromboembolic complications. The aim was to determine the indication for VKA use and factors associated with suboptimal anticoagulation control among patients in northern Tanzania.
View Article and Find Full Text PDFClin Appl Thromb Hemost
January 2025
Department of Cardiology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Background: Venous thromboembolism (VTE) comprises deep vein thrombosis (DVT) and pulmonary embolism (PE). Chronic thromboembolic pulmonary hypertension (CTEPH) typically arises from acute pulmonary embolism. The pathogenesis of them involves multiple risk factors such as genetic predisposition.
View Article and Find Full Text PDFAnn Med
December 2025
Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital, Tianjin, China.
Background And Objective: Janus kinase (JAK) inhibitors (JAKinibs) are effective for inflammatory bowel disease (IBD), but their cardiovascular safety is inconclusive. We aim to assess the cardiovascular risks associated with JAKinibs in IBD patients.
Patients And Methods: Systematic searches of seven databases and ClinicalTrials.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!